List of Excipients in Branded Drug BETAMETHASONE VALERATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	BETAMETHASONE VALERATE	betamethasone valerate	0168-0040	CETOSTEARYL ALCOHOL
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	BETAMETHASONE VALERATE	betamethasone valerate	0168-0040	CHLOROCRESOL
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	BETAMETHASONE VALERATE	betamethasone valerate	0168-0040	MINERAL OIL
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	BETAMETHASONE VALERATE	betamethasone valerate	0168-0040	PETROLATUM

Generic Drugs Containing BETAMETHASONE VALERATE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	betamethasone valerate	0472-0370	CETETH-20
Actavis Pharma Inc	betamethasone valerate	0472-0370	CETOSTEARYL ALCOHOL
Actavis Pharma Inc	betamethasone valerate	0472-0370	CHLOROCRESOL
Actavis Pharma Inc	betamethasone valerate	0472-0370	MINERAL OIL

What are the Most Frequently-Used Excipients in BETAMETHASONE VALERATE?

# Of NDCs	Excipient
6	ALCOHOL
5	ANHYDROUS CITRIC ACID
2	AQUA
2	BUTANE

Excipient Strategy and Commercial Opportunities for BETAMETHASONE VALERATE

Last updated: February 27, 2026

What is the Role of Excipients in BETAMETHASONE VALERATE Formulations?

Excipients in BETAMETHASONE VALERATE (BMV) formulations influence drug stability, bioavailability, patient compliance, and manufacturing processes. Common excipients include:

• Cream bases: Mineral oil, petrolatum, or lanolin for topical applications
• Suspending agents: Carbomers, cetostearyl alcohol to ensure uniform distribution
• Preservatives: Methylparaben, propylparaben for topical solutions
• Emulsifying agents: Polysorbates or glyceryl stearate for creams and lotions
• pH adjusters: Citric acid, sodium hydroxide to optimize drug stability

The selection depends on the dosage form (topical, aerosol, foam) and intended release profile.

How Does Excipient Strategy Impact Commercial Opportunities?

Innovative excipient use can expand product indications and improve competitive positioning. Strategies include:

• Enhanced bioavailability: Using penetration enhancers like dimethyl sulfoxide or ethanol to increase skin absorption.
• Prolonged release formulations: Incorporating polymers like hydroxypropyl methylcellulose (HPMC) to extend drug activity.
• Reduced irritation and improved tolerability: Selecting inert, skin-friendly excipients such as glycerin or allantoin.
• Formulation stability: Employing antioxidants (e.g., butylated hydroxytoluene) to prevent degradation during shelf life.

Adopting such strategies allows for premium pricing and broader market segmentation.

What Are the Key Commercial Opportunities for BETAMETHASONE VALERATE?

Market Landscape and Growth Drivers

• Global corticosteroid market: Valued at USD 7.4 billion in 2021, expected to grow at a CAGR of 4.2% through 2028 ([2]).
• Topical formulations dominate: Approximately 75% of BMV sales stem from dermatological products.
• Emerging markets: India, China, and Brazil show growing demand, driven by increasing dermatology awareness and healthcare infrastructure improvements.

Product Differentiation Potential

• Novel formulations: Liposomal creams and nanoemulsions enhancing skin penetration.
• Combination drugs: Pairing BMV with antibiotics or antifungals for complex dermatological conditions.
• Differentiated delivery systems: Metered-dose inhalers for respiratory indications or foam formulations for scalp application.

Patent and Regulatory Considerations

• Patent life varies by jurisdiction: The original patent on BMV expired in most major markets by 2005.
• Opportunity exists for formulation patents emphasizing excipient innovation or delivery systems.
• Regulatory pathways in the U.S. (FDA) and Europe (EMA) favor establishing bioequivalence or demonstrating improved safety profiles for new excipient combinations.

Manufacturing and Supply Chain Opportunities

• Contract manufacturing organizations (CMOs) note increased demand for specialized topical formulations.
• Regional sourcing of excipients may reduce costs and ensure supply chain resilience.

What Are the Challenges in Excipient and Product Development?

• Regulatory acceptance of novel excipients remains limited, especially for parenteral and inhalation products.
• Customer perceptions of excipient safety can influence market success; emphasis on inert, well-characterized excipients is necessary.
• Compatibility issues: Some excipients may react with BMV or impact stability, requiring extensive testing.

Which Trends Are Shaping Future Opportunities?

• Green formulations: Use of biodegradable, hypoallergenic excipients aligns with sustainability trends.
• Personalized dermatology: Tailored drug delivery systems based on patient skin type increases treatment efficacy.
• Combination therapies: Expanding indications through fixed-dose combinations enhances adherence and therapeutic outcomes.

Summary of Commercial Strategies

Approach	Description	Benefit
Excipient innovation	Use of penetration enhancers, stabilizers	Increased efficacy, patentable formulations
Delivery system enhancement	Liposomes, nanoemulsions	Improved bioavailability, competitive advantage
Market expansion	Emerging markets, product combos	Increased sales volume, portfolio diversification

Key Takeaways

• Excipient choices directly impact the efficacy, stability, and marketability of BETAMETHASONE VALERATE products.
• Innovation in formulation can lead to premium pricing and new indications.
• Regional market dynamics favor product differentiation and supply chain agility.
• Regulatory pathways favor formulations with established excipient safety profiles.
• Emphasizing sustainability and personalized medicine can unlock future growth.

FAQs

1. What excipients are commonly used in BETAMETHASONE VALERATE topical formulations?
Mineral oil, petrolatum, carbomers, preservatives like methylparaben, emulsifying agents such as glyceryl stearate, and pH adjusters are typical.

2. How can excipient strategy influence patent opportunities?
Using novel excipient combinations or delivery systems can create patentable formulations, extending commercial exclusivity.

3. Are there safety concerns with excipients in BETAMETHASONE VALERATE products?
Yes. Regulatory agencies prefer excipients with established safety profiles; novel excipients require extensive safety validation.

4. Which regions present the most growth opportunities for BETAMETHASONE VALERATE products?
Emerging markets such as India, China, and Brazil demonstrate increasing demand driven by dermatological needs and economic development.

5. What future trends could shape BETAMETHASONE VALERATE development?
Green formulations, personalized topical treatments, and combination therapies are emerging trends.

---

References

[1] Smith, J., & Liu, X. (2022). Excipient Optimization in Dermatological Drug Delivery. International Journal of Pharmaceutics, 600, 120567.
[2] MarketWatch. (2022). Corticosteroids Market Size, Trends, and Forecast. Retrieved from https://www.marketwatch.com/